Oct. 27 at 7:39 PM
$AVXL Ulla Wändel Liminga is heading the chair of Pharmacovigilance Risk Assesment Commitee (PRAC). On 10/20 they published meeting minutes blarc being in preD-180 scope https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-1-4-september-2025_en.pdf
The Swedish regional health authorities published a report on blarc in June this year which was cautiously optimistic. The authorities recognize real disease-modifying potential and a major convenience/safety advantage, but they also emphasize: Early stage evidence is not yet definitive, Clinical magnitude at 48 weeks is borderline, Long-term benefit is promising but needs final confirmation - nothing new.
http://samverkanlakemedel.se/download/18.6be0dfcb19937114a3a571b/1758861823320/Blarkamesin-vid-Alzheimers-sjukdom-tidig-bedomningsrapport-250619.pdf
That's after UK, DK, NL pre-registration activities with the governement for reimbursement as discussed yesterday and today on this board. Most countries cannot before approval. Norway also has blarc on the radar
https://www.nyemetoder.no/4a79df/contentassets/55df15e45e2a4e9083a95e751a772ff7/2025/nye-legemidler-som-ikke-har-mt--september-2025.pdf
Italy too
https://www.aifa.gov.it/documents/20142/1108722/Horizon_Scanning_2025.pdf?utm_source=chatgpt.com
